SCHEMBL8670812

SCHEMBL8670812

c1ccc(CCc2ccc3ccccc3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.59
CYP1A2 P05177 2/20 0.58
CYP2A6 P11509 1/20 0.58
SIGMAR1 Q99720 3/20 0.55
KMT2A Q03164 1/20 0.55
HRH3 Q9Y5N1 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
BCHE P06276 3/20 0.51
SOX18 P35713 1/20 0.51
MAOA P21397 2/20 0.50
MAOB P27338 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240981 0.93 CYP1A2 (0.65) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL29560700 0.93 CYP1A2 (0.65) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL3024493 0.91 CYP1A2 (0.65) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL3941594 0.91 CYP1A2 (0.65) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL29477161 0.91 CYP1A2 (0.65) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL28746131 0.85 CYP1A2 (0.58) PLAUCYP1A2CYP2A6SIGMAR1HRH3
SCHEMBL9827506 0.85 MAOB (0.61) PLAUCYP1A2CYP2A6SIGMAR1HRH3
SCHEMBL13946261 0.85 CYP2A6 (0.58) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL21517641 0.85 ESR1 (0.58) PLAUCYP1A2CYP2A6SIGMAR1KMT2A
SCHEMBL6295016 0.84 CYP1A2 (0.56) PLAUCYP1A2CYP2A6SIGMAR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410116-B2 Compounds and use thereof in methods of treatment THE UNIVERSITY OF QUEENSLAND (AU) 2025-09-09 US disclosed
CN-115772058-B Reduction method of aromatic internal olefins 南通大学 2024-08-16 CN disclosed
US-20240002326-A1 COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT THE UNIVERSITY OF QUEENSLAND (AU) 2024-01-04 US disclosed
CN-114345370-B Method for reduction cross coupling of photocatalytic aromatic olefin and halogenated hydrocarbon 陕西师范大学 2023-07-21 CN disclosed
US-20230100768-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES THE UNIVERSITY OF QUEENSLAND (AU) 2023-03-30 US disclosed
CN-115772058-A Reduction method of aromatic internal olefin 南通大学 2023-03-10 CN disclosed
US-11434190-B2 Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases THE UNIVERSITY OF QUEENSLAND (AU) 2022-09-06 US disclosed
CN-114345370-A Method for reducing and cross-coupling aromatic olefin and halogenated hydrocarbon through photocatalysis 陕西师范大学 2022-04-15 CN disclosed
US-20190337880-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES THE UNIVERSITY OF QUEENSLAND (AU) 2019-11-07 US disclosed
CN-101175713-B Acrylic ester compound and manufacturing intermediate thereof, method for manufacturing acrylic ester compound, and latent electrostatic image bearing member, image forming method, image forming apparatus and photocopying cartridge RICOH CO LTD 2013-05-15 CN disclosed
CN-101175713-A Acrylic ester compound and manufacturing intermediate thereof, method for manufacturing acrylic ester compound, and latent electrostatic image bearing member, image forming method, image forming appar RICOH KK (JP) 2008-05-07 CN disclosed
CN-1291958-C Naphthacridine derivative and liquid crystal composite containing it DAINIPPON INK CHEMICAL IND CO (JP) 2006-12-27 CN disclosed
US-5811422-A USEFUL FOR TREATING VIRAL INFECTIONS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-09-22 US disclosed
US-5610294-A VIRAL TREATMENT THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337880-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES SOX18, PROX1, RUNX1 PLAU 1902/4885CYP1A2 4690/4885CYP2A6 4670/4885
US-11434190-B2 Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases SOX18, PROX1, RUNX1 PLAU 1902/4885CYP1A2 4690/4885CYP2A6 4670/4885
US-20230100768-A1 INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES SOX18, PROX1, RUNX1 PLAU 1932/4885CYP1A2 4661/4885CYP2A6 4688/4885
US-12410116-B2 Compounds and use thereof in methods of treatment SOX18, PROX1, RUNX1 PLAU 1921/4885CYP1A2 4644/4885CYP2A6 4617/4885
US-20240002326-A1 COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT SOX18, PROX1, RUNX1 PLAU 1921/4885CYP1A2 4644/4885CYP2A6 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.